Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...
Beyond being a big deal for Takeda, which is the state’s largest life sciences employer and is relocating its Central Square ...
The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...
Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®â€“ (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous ...
Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running ...
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch ...
Takeda Pharmaceutical 45020.69%increase; green up pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback